Royalty Pharma plc (RPRX) Stock Analysis & Investment Frameworks
Royalty Pharma plc (RPRX) stock analysis on Invetso. Review Royalty Pharma plc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Royalty Pharma plc Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: US
Royalty Pharma plc Key Financial Metrics
- Market Cap: $27.67B
- Revenue: $2.38B
- P/E Ratio: 35.92
- ROE: 12.25%
- ROIC: 8.96%
- Dividend Yield: 1.49%
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc Investment Frameworks
Invetso analyzes Royalty Pharma plc (RPRX) across the following frameworks:
- Royalty Pharma plc 10Y Growth Potential
- Royalty Pharma plc Scenario Analysis
- Royalty Pharma plc Risks & Opportunities
- Royalty Pharma plc Economic Moat
- Royalty Pharma plc Business Model
- Royalty Pharma plc Management
- Royalty Pharma plc SWOT Analysis
- Royalty Pharma plc Porter's 5 Forces
- Royalty Pharma plc PESTLE Analysis
- Royalty Pharma plc ESG Analysis